Peripheral T Cell Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
2022-04-01
Apr 1, 2022
A
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Transformed Mycosis Fungoides
  • Birmingham, Alabama
  • +68 more
2022-03-28
Mar 28, 2022
S
Recruiting
  • Hodgkin Disease
  • Peripheral T Cell Lymphoma
  • brentuximab vedotin
  • +3 more
  • Birmingham, Alabama
  • +53 more
2022-03-18
Mar 18, 2022
S
Not yet recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • (no location specified)
2022-03-18
Mar 18, 2022
U
Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
2022-03-04
Mar 4, 2022
S
Not yet recruiting
  • Peripheral T Cell Lymphoma
  • +3 more
  • STI-3031
  • (no location specified)
2022-03-14
Mar 14, 2022
N
Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Hefei, Anhui, China
  • +2 more
2022-02-25
Feb 25, 2022
U
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
2022-02-03
Feb 3, 2022
W
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
2022-02-14
Feb 14, 2022
T
Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
2021-12-30
Dec 30, 2021
T
Recruiting
  • Peripheral T Cell Lymphoma
  • Relapse/Recurrence
  • Antwerpen, Belgium
  • +38 more
2021-12-06
Dec 6, 2021
B
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +7 more
  • BR101801 (Phase Ia)
  • +2 more
  • Seoul, Korea, Republic of
  • +2 more
2021-11-19
Nov 19, 2021
T
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
2021-09-29
Sep 29, 2021
T
Recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
2021-10-04
Oct 4, 2021
U
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Birmingham, United Kingdom
  • +12 more
2021-10-01
Oct 1, 2021
N
Recruiting
  • NK-Cell Lymphoma
  • +2 more
  • San Francisco, California
  • +1 more
2021-09-01
Sep 1, 2021
C
Recruiting
  • Treatment-naïve
  • Peripheral T Cell Lymphoma
  • Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
  • Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2021-07-26
Jul 26, 2021
B
Completed
  • Peripheral T Cell Lymphoma
  • +18 more
  • Lake Success, New York
  • +33 more
2021-07-05
Jul 5, 2021
D
Recruiting
  • Cutaneous T Cell Lymphoma
  • Peripheral T Cell Lymphoma
  • Microdevices
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-06-22
Jun 22, 2021
S
Recruiting
  • Peripheral T Cell Lymphoma
  • +4 more
  • anti-TRBC1 CAR-T cell therapy
  • Shanghai, Shanghai, China
    Xianmin Song
2021-03-31
Mar 31, 2021
G
Recruiting
  • Peripheral T Cell Lymphoma
  • GB226
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
2021-03-02
Mar 2, 2021
C
Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Chidamide
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2020-12-11
Dec 11, 2020
P
Recruiting
  • Peripheral T Cell Lymphoma
  • Transplant, Autologous
  • Beijing, China
    Beijing Cancer Hospital
2020-12-02
Dec 2, 2020